hrs4r
 I want to donate

The Research Group in Radiation Oncology and Medical Physics of Girona (ONCORFIM Girona) is a multidisciplinary group whose mission is to improve oncological outcomes and quality of life of our patients by applying new technologies.

The way to achieve this goal, will be from the following key points for us.

  1. Minimize the dose received in critical organs and improve clinical outcomes.
  2. Predict response and toxicity to radiotherapy treatment.
  3. Use new digital technologies to achieve the previously described (ICOnnecta't).
Main lines of research

Line 1: Prevention of cardiotoxicity and radiotherapy in breast cancer.

Prevention of cardiotoxicity in breast cancer patients undergoing cardiotoxic treatments such as radiotherapy (Arantxa Eraso).

Cardiotoxicity in external radiotherapy: clinical impact of the dose delivered (Ingrid Romera).

The following projects are underway within this line:

  • Horizon 2020 Project Medirad. Early detection of cardiovascular changes after radiotherapy in breast cancer. Reference: EARLY-HEART. Principal Investigator: Arantxa Eraso.
  • Development and clinical implementation of the DIFGI device in forced inspiration techniques maintained in left breast cancer treatments with external radiotherapy to reduce the dose to the heart. Doctoral candidate: Ingrid Romera. Thesis supervisors: Joan Carles Vilanova and Rafael Fuentes.
  • Impact of a structured physical exercise program and control of cardiovascular risk factors in the primary prevention of cardiotoxicity in breast cancer patients undergoing cardiotoxic treatments: Estudi PREV (Arantxa Eraso).

Line 2: Technological advances in radiotherapy (ablative radiotherapy, intraoperative radiotherapy techniques, new techniques and quality in radiotherapy).

  • Use of Intraoperative Radiotherapy in breast neoplasia. Reference: RIOMA. Principal Investigator: Arantxa Eraso.
  • Phase II trial of Electronic Brachytherapy in the post-surgical treatment of endometrial cancer (Hugo Rosales and Ester Oliva).
  • Ablative radiotherapy in different locations, the most innovative being the Pancreatic SBRT (Eugeni Canals).
  • Dose determination, technology and quality in external radiotherapy (Diego Jurado Bruggeman).
  • Clinical impact of dose calculation in external radiotherapy and associated technological and quality assurance aspects (Carles Muñoz Montplet).

Line 3: Biomarkers of response to radiotherapy.

  • BIOMARKERS AS PREDICTORS OF RESPONSE IN RECTAL CANCER.
  • Radiogenomics: identification of biomarkers by genome-wide association studies (GWAS) and exome sequencing (WES) in extreme phenotypes.
  • Radiosensitivity studies in cancer patients at high risk of toxicity. Reference: PRED-RAD. Collaborating researchers: Arantxa Eraso, Rafael Fuentes and Àlvar Roselló.

Line 4: e-Health and humanization in the Radiation Oncology process.

  • Online screening and monitoring of symptomatology secondary to Radiation therapy treatment of digestive tumors: a prospective controlled clinical trial.
  • Prostate Cancer Outcomes Global initiative to compare and reduce variation in localized prostate cancer. Reference: PCO-CRV. Principal Investigator: Àlvar Roselló.

IROCATES: Quality improvement in Radiation Oncology through Clinical Audits. Principal Investigators: Carles Muñoz and Àlvar Roselló.

Strategic objectives

The objective of the group is to conduct research in the hospital setting in an area in which technological advances are oriented towards the modification of clinical practice towards personalized and precision medicine: Treatment for the right patient vs. treatment for a disease.

Publications
0

Management of high-risk and post-operative non-metastatic prostate cancer in Catalonia: an expert Delphi consensus

CLINICAL & TRANSLATIONAL ONCOLOGY, 2023, 25, 1017-1023 dx.doi.org/10.1007/s12094-022-03005-4

Rubió-Casadevall J, Ciurana E, Puigdemont M, Sanvisens A, Marruecos J, Miró J, Urban A, Palhua RL, Martín-Romero F, Ortiz-Duran MR, Marcos-Gragera R

Population-Based Analysis of Trends in Incidence and Survival of Human Papilloma Virus-Related Oropharyngeal Cancer in a Low-Burden Region of Southern Europe

INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2022, 19 dx.doi.org/10.3390/ijerph19084802

Jurado-Bruggeman, D, Munoz-Montplet, C, Hernandez, V, Saez, J, Fuentes-Raspall, R

Impact of the dose quantity used in MV photon optimization on dose distribution, robustness, and complexity

MEDICAL PHYSICS, 2022, 49, 648-665 dx.doi.org/10.1002/mp.15389

Fizazi, K, Foulon, S, Carles, J, Roubaud, G, McDermott, R, Flechon, A, Tombal, B, Supiot, S, Berthold, D, Ronchin, P, Kacso, G, Gravis, G, Calabro, F, Berdah, JF, Hasbini, A, Silva, M, Thiery-Vuillemin, A, Latorzeff, I, Mourey, L, Laguerre, B, Abadie-Lacourtoisie, S, Martin, E, El Kouri, C, Escande, A, Rosello, A, Magne, N, Schlurmann, F, Priou, F, Chand-Fouche, ME, Freixa, SV, Jamaluddin, M, Rieger, I, Bossi, A

Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 x 2 factorial design

Lancet, 2022, 399, 1695-1707 dx.doi.org/10.1016/S0140-6736(22)00367-1

Humbert-Vidan, L, Hansen, CR, Fuller, CD, Petit, S, Van der Schaaf, A, Van Dijk, LV, Verduijn, GM, Langendijk, H, Munoz-Montplet, C, Heemsbergen, W, Witjes, M, Mohamed, ASR, Khan, AA, Querol, JM, Cancio, IO, Patel, V, King, AP, Johansen, J, Urbano, TG

Protocol Letter: A multi-institutional retrospective case-control cohort investigating PREDiction models for mandibular OsteoRadioNecrosis in head and neck cancer (PREDMORN)

RADIOTHERAPY AND ONCOLOGY, 2022, 176, 99-100 dx.doi.org/10.1016/j.radonc.2022.09.014

Peremiquel-Trillas P, Saura-Lázaro A, Benavente-Moreno Y, Casabonne D, Loureiro E, Cabrera S, Duran A, Garrote L, Brao I, Trelis J, Galán M, Soler F, Julià J, Cortasa D, Domínguez MÁ, Albasanz-Puig A, Gudiol C, Ramírez-Tarruella D, Muniesa J, Rivas JP, Muñoz-Montplet C, Sedano A, Plans À, Calvo-Cerrada B, Calle C, Clopés A, Carnicer-Pont D, Alemany L, Fernández E

COVID-19 among workers of a comprehensive cancer centre between first and second epidemic waves (2020): a seroprevalence study in Catalonia, Spain.

BMJ Open, 2022, 12 dx.doi.org/10.1136/bmjopen-2021-056637

Laplana, M, Garcia-Marqueta, M, Sanchez-Fernandez, JJ, Martinez-Perez, E, Perez-Montero, H, Martinez-Montesinos, I, Eraso, A, Saldana, P, Martin, R, Martin, MI, Pla, MJ, Garcia-Tejedor, A, Guedea, F

Effectiveness and safety of intraoperative radiotherapy (IORT) with low-energy X-rays (INTRABEAM(R)) for accelerated partial breast irradiation (APBI)

CLINICAL & TRANSLATIONAL ONCOLOGY, 2022, 24, 1732-1743 dx.doi.org/10.1007/s12094-022-02823-w

Eraso A, Sanz J, Mollà M, Reyes V, Pedro A, Arenas M, Martinez E, Ballester R, Cambra MJ, García V, Prades JL, Borras JM, Algara M

Evidence-based guidelines for hypofractionated radiation in breast cancer: conclusions of the Catalan expert working group.

CLINICAL & TRANSLATIONAL ONCOLOGY, 2022, 24, 1580-1587 dx.doi.org/10.1007/s12094-022-02798-8

Locquet, M, Spoor, D, Crijns, A, van der Harst, P, Eraso, A, Guedea, F, Fiuza, M, Santos, SCR, Combs, S, Borm, K, Mousseaux, E, Gencer, U, Frija, G, Cardis, E, Langendijk, H, Jacob, S

Subclinical Left Ventricular Dysfunction Detected by Speckle-Tracking Echocardiography in Breast Cancer Patients Treated With Radiation Therapy: A Six-Month Follow-Up Analysis (MEDIRAD EARLY-HEART study)

Frontiers in oncology, 2022, 12, 883679-883679 dx.doi.org/10.3389/fonc.2022.883679

Esteve-Codina A, Alameda F, Carrato C, Pineda E, Arpí O, Martinez Garcia M, Mallo M, Gut M, Dabad M, Tortosa A, Del Barco S, Capellades J, Puig J, Gallego O, Pujol T, Oleaga L, Gil-Gil MJ, de Quintana-Schmidt C, Valduvieco I, Martinez-Cardus A, Bellosillo B, Muñoz-Mármol AM, Esteve A, Domenech M, Camins A, Craven-Bartle J, Villa S, Marruecos J, Domenech S, de la Iglesia N, Balana C

RNA sequencing and Immunohistochemistry Reveal ZFN7 as a Stronger Marker of Survival than Molecular Subtypes in G-CIMP-negative Glioblastoma

CLINICAL CANCER RESEARCH, 2021, 27, 645-655 dx.doi.org/10.1158/1078-0432.CCR-20-2141
Competitive projects
Codi oficial: ADARNAT I Start date:09/12/2022 Data fi: 09/12/2027 Investigador/a principal: ARANTXA ERASO URIÉN Organisme finançador: ASSOCIACIÓ ESPANYOLA CONTRA EL CÀNCER Ajuda: 0 €
Transfer
Patents

Carles Muñoz, Ingrid Romera, Diego Jurado, Jordi Marruecos, Salvador Bou, Roger Grèbol.
DEVICE FOR THE POSITIONING OF PATIENTS IN RADIOTHERAPY TREATMENTS
Número de publicació: ES1165083
Data de publicació: 2016-09-21

Job offers

Team

If you are a researcher and you are interested in collaborating with any of our research groups, please fill in this form.
I am interested in
If you are a student or you want to do an internship with any of our research groups, please fill in this form.
I am interested in

About IDIBGI!

menu